Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
CMPS Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CMPS Stock 12 Month Forecast
Average Price Target
$19.29
▲(325.83%Upside)
| Highest Price Target$45.00 | Average Price Target$19.29 | Lowest Price Target$11.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Cantor Fitzgerald
$12
Buy
164.90%
Upside
Initiated
05/27/25
TD Cowen
$23
Buy
407.73%
Upside
Reiterated
05/27/25
Morgan Stanley
$17
Buy
275.28%
Upside
Reiterated
05/15/25
Maxim Group
$12
Buy
164.90%
Upside
Reiterated
05/13/25
H.C. Wainwright
$45
Buy
893.38%
Upside
Reiterated
05/12/25
RBC Capital
$15
Buy
231.13%
Upside
Reiterated
05/08/25
Stifel Nicolaus
$11
Buy
142.83%
Upside
Reiterated
04/11/25
BTIG
$12
Buy
164.90%
Upside
Reiterated
03/02/25
Optimistic Buy Rating for COMPASS Pathways: Strategic Trials and Strong Financial Position Bolster Confidence in COMP360's PotentialWe see this approach as reflecting the all-in efforts to minimize the effects of this first release on subsequent readouts. At the root of this approach is the unusually low placebo effects seen for COMP360 relative to most drugs tested in TRD and MDD. The best explanation we have heard for the effect is that "one-and-done" approaches like COMP360 are expected to have lower placebo effects than drugs involving QD or BID reminders to patients that they are in a clinical trial. Overall, this decision in the upcoming readout, although frustrating for investors, appears to be aimed at preserving the integrity of the blinded 26-week readout in the 005 trial. Additionally, it is also likely to prevent any effects on the more-important 006 trial. Importantly, the call confirmed that 005 and 006 data remain on track for 2Q25 and 2H26, respectively.
Canaccord Genuity
$23→$15
Buy
231.13%
Upside
Reiterated
02/28/25
Lucid Capital
$30→$9
Buy
98.68%
Upside
Reiterated
01/27/25
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$14
Buy
209.05%
Upside
Assigned
11/01/24
We think this setup explains the stock move down today + over the last couple months.
Oppenheimer
$25
Buy
451.88%
Upside
Reiterated
08/02/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Cantor Fitzgerald
$12
Buy
164.90%
Upside
Initiated
05/27/25
TD Cowen
$23
Buy
407.73%
Upside
Reiterated
05/27/25
Morgan Stanley
$17
Buy
275.28%
Upside
Reiterated
05/15/25
Maxim Group
$12
Buy
164.90%
Upside
Reiterated
05/13/25
H.C. Wainwright
$45
Buy
893.38%
Upside
Reiterated
05/12/25
RBC Capital
$15
Buy
231.13%
Upside
Reiterated
05/08/25
Stifel Nicolaus
$11
Buy
142.83%
Upside
Reiterated
04/11/25
BTIG
$12
Buy
164.90%
Upside
Reiterated
03/02/25
Optimistic Buy Rating for COMPASS Pathways: Strategic Trials and Strong Financial Position Bolster Confidence in COMP360's PotentialWe see this approach as reflecting the all-in efforts to minimize the effects of this first release on subsequent readouts. At the root of this approach is the unusually low placebo effects seen for COMP360 relative to most drugs tested in TRD and MDD. The best explanation we have heard for the effect is that "one-and-done" approaches like COMP360 are expected to have lower placebo effects than drugs involving QD or BID reminders to patients that they are in a clinical trial. Overall, this decision in the upcoming readout, although frustrating for investors, appears to be aimed at preserving the integrity of the blinded 26-week readout in the 005 trial. Additionally, it is also likely to prevent any effects on the more-important 006 trial. Importantly, the call confirmed that 005 and 006 data remain on track for 2Q25 and 2H26, respectively.
Canaccord Genuity
$23→$15
Buy
231.13%
Upside
Reiterated
02/28/25
Lucid Capital
$30→$9
Buy
98.68%
Upside
Reiterated
01/27/25
Unknown AnalystEvercore ISI
Not Ranked
Evercore ISI
$14
Buy
209.05%
Upside
Assigned
11/01/24
We think this setup explains the stock move down today + over the last couple months.
Oppenheimer
$25
Buy
451.88%
Upside
Reiterated
08/02/24
Best Analysts Covering COMPASS Pathways
1 Month
xxx
Success Rate
10/22 ratings generated profit
Average Return
-0.43%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 45.45% of your transactions generating a profit, with an average return of -0.43% per trade.
3 Months
xxx
Success Rate
5/10 ratings generated profit
Average Return
+2.27%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.27% per trade.
1 Year
Success Rate
2/10 ratings generated profit
Average Return
-20.97%
reiterated a buy rating 11 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -20.97% per trade.
2 Years
xxx
Success Rate
2/10 ratings generated profit
Average Return
-29.22%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -29.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CMPS Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
12
16
11
10
11
Buy
0
0
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
16
12
11
12
Each month's total comprises the sum of three months' worth of ratings.
CMPS Financial Forecast
CMPS Stock Forecast FAQ
What is CMPS’s average 12-month price target, according to analysts?
Based on analyst ratings, COMPASS Pathways’s 12-month average price target is 19.29.
What is CMPS’s upside potential, based on the analysts’ average price target?
COMPASS Pathways has 325.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CMPS a Buy, Sell or Hold?
COMPASS Pathways has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is COMPASS Pathways’s price target?
The average price target for COMPASS Pathways is 19.29. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $11.00. The average price target represents 325.83% Increase from the current price of $4.53.
The highest analyst price target is $45.00 ,the lowest forecast is $11.00. The average price target represents 325.83% Increase from the current price of $4.53.
What do analysts say about COMPASS Pathways?
COMPASS Pathways’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of CMPS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.